MARINA FLABOREA MAZZOCO
Projetos de Pesquisa
Unidades Organizacionais
Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina
SCPSIQ-62, Hospital Universitário
SCPSIQ-62, Hospital Universitário
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
bookPart História da psiquiatria(2019) MAZZOCO, Marina Flaborea; FUKUTI, Pedro; FERREIRA, Pedro Mendonça; CASTELLANA, Gustavo BoninibookPart Consciência e atenção(2021) NOGUEIRA, Juliana Hangai Vaz Guimarães; MAZZOCO, Marina Flaborea; DIAS, Yuri Tebelskis Nunes; GALLUCCI NETO, José; MARCHETTI, Renato Luiz- COMVC-19: A Program to protect healthcare workers' mental health during the COVID-19 Pandemic. What we have learned(2021) FUKUTI, Pedro; UCHOA, Caroline Louise Mesquita; MAZZOCO, Marina Flaborea; CRUZ, Isabella D'Andrea Garcia da; ECHEGARAY, Mariana V. F.; HUMES, Eduardo de Castro; SILVEIRA, Julia Belizario; SANTI, Talita Di; MIGUEL, Euripedes Constantino; CORCHST, FelipeOBJECTIVE: In 2020, the COVID-19 pandemic brought a work and stress overload to healthcare workers, increasing their vulnerability to mental health impairments. In response, the authors created the COMVC-19 program. The program offered preventive actions and mental health treatment for the 22,000 workers of The Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP). This paper aims to describe its implementation and share what we have learned from this experience. METHODS: Workers were able to easily access the program through a 24/7 hotline. Additionally, a mobile phone app that screened for signs and symptoms of emotional distress and offered psychoeducation and/or referral to treatment was made available. Data from both these sources as well as any subsequent psychiatric evaluations were collected. RESULTS: The first 20 weeks of our project revealed that most participants were female, and part of the nursing staff working directly with COVID-19 patients. The most frequently reported symptoms were: anxiety, depression and sleep disturbances. The most common diagnoses were Adjustment, Anxiety, and Mood disorders. CONCLUSIONS: Implementing a mental health program in a multimodal intervention was feasible in a major quaternary public hospital. Our data also suggests that preventive actions should primarily be aimed at anxiety and depression symptoms, with a particular focus on the nursing staff.
- How Institutions Can Protect the Mental Health and Psychosocial Well-Being of Their Healthcare Workers in the Current COVID-19 Pandemic(2020) FUKUTI, Pedro; UCHOA, Caroline Louise Mesquita; MAZZOCO, Marina Flaborea; CORCHS, Felipe; KAMITSUJI, Carla Satie; ROSSI, Luciane De; RIOS, Izabel Cristina; LANCMAN, Selma; BONFA, Eloisa; BARROS-FILHO, Tarcisio Eloy Pessoa de; MIGUEL, Euripedes Constantino
bookPart Manifestações psiquiátricas no contexto das pandemias: Covid-19(2021) FUKUTI, Pedro; CRUZ, Isabella D´Andrea Garcia da; SANTI, Talita Di; PENTEADO, Camila Truzzi; CHO, Aline Jimi Myung; SALDANHA, Natalia L.; UCHôA, Louise Mesquita; MAZZOCO, Marina Flaborea- Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia(2013) ZAI, Clement C.; TIWARI, Arun K.; MAZZOCO, Marina; LUCA, Vincenzo de; MUELLER, Daniel J.; SHAIKH, Sajid A.; LOHOFF, Falk W.; FREEMAN, Natalie; VOINESKOS, Aristotle N.; POTKIN, Steven G.; LIEBERMAN, Jeffrey A.; MELTZER, Herbert Y.; REMINGTON, Gary; KENNEDY, James L.Tardive dyskinesia (TD) is an involuntary movement disorder that can occur in up to 25% of patients receiving long-term first-generation antipsychotic treatment. Its etiology is unclear, but family studies suggest that genetic factors play an important role in contributing to risk for TD. The vesicular monoamine transporter 2 (VMAT2) is an interesting candidate for genetic studies of TD because it regulates the release of neurotransmitters implicated in TD, including dopamine, serotonin, and GABA. VMAT2 is also a target of tetrabenazine, a drug used in the treatment of hyperkinetic movement disorders, including TD. We examined nine single-nucleotide polymorphisms (SNPs) in the SLC18A2 gene that encodes VMAT2 for association with TD in our sample of chronic schizophrenia patients (n = 217). We found a number of SNPs to be nominally associated with TD occurrence and the Abnormal Involuntary Movement Scale (AIMS), including the rs2015586 marker which was previously found associated with TO in the CATIE sample (Tsai et al., 2010), as well as the rs363224 marker, with the low-expression AA genotype appearing to be protective against TD (p = 0.005). We further found the rs363224 marker to interact with the putative functional D2 receptor rs6277 (C957T) polymorphism (p = 0.001), supporting the dopamine hypothesis of TD. Pending further replication, VMAT2 may be considered a therapeutic target for the treatment and/or prevention of TD.
bookPart Síndromes psiquiátricas e trauma cranioencefálico(2021) MAZZOCO, Marina Flaborea; DIAS, Yuri Tebelskis Nunes; GALLUCCI NETO, José